What the test looks for
Detection of KRAS and NRAS mutations in exons 2, 3 and 4 (codons 12, 13, 59, 61, 117 and 146).
Only patients whose tumour carries no RAS mutation ("RAS wild-type" status) can benefit from anti-EGFR antibodies. The report also states whether the KRAS G12C mutation, the target of specific treatments, is present.
This test is often requested together with BRAF V600E mutation testing and MSI status.
Required sample
- FFPE block of the primary tumour or a metastasis, or 10 unstained slides with one H&E slide.
- Tumour cellularity of at least 20% recommended.
- Pathology report enclosed.